> ## Content Index
> Fetch the complete content index at: https://www.bullished.co/llms.txt
> Use this file to discover other available public pages before exploring further.

# Rezolute Has $90.0 Million In Cash And Investments As Drug Results Approach
- URL: https://www.bullished.co/rezolute-has-90-0-million-in-cash-and-investments-as-drug-results-approach-4d39640d/
- Published: 2026-11-06T14:06:50.000Z
- Updated: 2026-11-06T14:06:50.000Z
- Description: The quarterly loss widened to $18.5 million, while Rezolute plans approval applications for one or potentially both indications in 2027.
- Author: Matteo Parrino
- Tags: SEC Filings, RZLT, Industry: Healthcare

[Rezolute](https://www.bullished.co/tag/rzlt/), which develops therapies for dangerously low blood sugar caused by excess insulin activity, ended September with [$90.0 million](https://www.sec.gov/Archives/edgar/data/0001509261/000110465926123336/tm2628931d2%5F8k.htm?ref=bullished.co) in cash and investments, down from $107.8 million at June 30, according to results accompanying its Thursday SEC filing. The company expects initial results from its tumor-related disease trial by mid-December 2026 and plans to seek approval for its experimental drug ersodetug in 2027.

## Lower Spending, A Wider Loss

Rezolute’s fiscal first-quarter [net loss reached](https://www.sec.gov/Archives/edgar/data/0001509261/000110465926123336/tm2628931d2%5Fex99-1.htm?ref=bullished.co) $18.5 million, compared with $18.2 million a year earlier. The loss per share remained $0.18.

Operating expenses declined to $19.385 million from $19.817 million in the year-earlier quarter, while net non-operating income fell to $898,000 from $1.667 million. Working capital—the difference between short-term assets and short-term obligations—stood at $84.370 million, versus $99.093 million at June 30.

Research and development spending was [$12.8 million](https://www.globenewswire.com/news-release/2026/11/05/3397072/0/en/rezolute-reports-first-quarter-fiscal-2027-financial-results-and-provides-business-update.html?ref=bullished.co), against $13.1 million a year earlier. Lower ersodetug manufacturing and patient-affairs costs outweighed increased employee stock compensation; stock compensation in research spending rose to $1.5 million from $1.2 million.

Administrative expenses were [$6.6 million](https://www.globenewswire.com/news-release/2026/11/05/3397072/0/en/rezolute-reports-first-quarter-fiscal-2027-financial-results-and-provides-business-update.html?ref=bullished.co), compared with $6.7 million. Professional fees declined, partly offset by employee stock compensation, which rose to $1.8 million from $1.4 million.

## Tumor Trial Enrollment Is Complete

Enrollment has finished in Rezolute’s [late-stage tumor study](https://www.sec.gov/Archives/edgar/data/0001509261/000110465926123336/tm2628931d2%5Fex99-1.htm?ref=bullished.co), which involves up to 16 hospitalized participants. Everyone receives ersodetug, and the study has no comparison group.

Results announced earlier this year showed that seven of the first eight participants met the study’s main response criterion. All seven also stopped receiving intravenous glucose completely during treatment with ersodetug.

The remaining participant stopped taking the study drug shortly after joining to pursue hospice care at home and died a week later from cancer progression. Rezolute counts that participant as a non-responder for the trial’s main measure.

Rezolute described tolerability as favorable and said the study has had no reported drug-related safety findings so far. Ersodetug remains investigational; health authorities have not approved its safety and effectiveness claims.

## A Missed Goal, An Application Path

The congenital hyperinsulinism program presents a different evidence picture. Its late-stage trial compared ersodetug with placebo but missed its main goal: finger-stick readings did not establish a statistically significant reduction in low-blood-sugar events versus placebo.

Continuous glucose monitoring produced improvements across multiple measures in both treatment groups, according to Rezolute. A continuing extension study, in which participants know the treatment they receive, has high participation and signs of better blood-sugar control, including reduced use of existing therapies.

In October 2026, the FDA reviewed additional data it had requested and recommended an approval application for congenital hyperinsulinism after a pre-application meeting, Rezolute said. The company cautioned that the agency could still judge the overall evidence insufficient to support approval.

Ersodetug is an antibody given intravenously that aims to reduce excessive activation of insulin receptors. Rezolute has no approved products and is studying the drug for congenital disease, which affects children, and tumor-related disease. An expanded access program also supplies it to patients unable to join a clinical trial.

Rezolute’s commercial outlook includes a potential $5 billion combined market opportunity, the company said in describing its launch strategy. Its plan is to submit an FDA approval application for one or potentially both indications in 2027.

The next scheduled clinical milestone is the tumor study’s initial results, expected by mid-December 2026.

Learn

- [Item 2.02: results of operations →](https://www.bullished.co/learn/8-k-items-explained/#item-202-results-of-operations)  
From 8-K Items Explained: What Every Item Code From 1.01 To 9.01 Tells You, With Examples

### Sources

- [8-K Filing — Rezolute, Inc. (RZLT)](https://www.sec.gov/Archives/edgar/data/0001509261/000110465926123336/tm2628931d2%5F8k.htm?ref=bullished.co) — SEC EDGAR
- [Exhibit tm2628931d2\_ex99-1.htm — Rezolute, Inc. 8-K exhibit](https://www.sec.gov/Archives/edgar/data/0001509261/000110465926123336/tm2628931d2%5Fex99-1.htm?ref=bullished.co) — SEC EDGAR
- [Rezolute Reports First Quarter Fiscal 2027 Financial](https://www.globenewswire.com/news-release/2026/11/05/3397072/0/en/rezolute-reports-first-quarter-fiscal-2027-financial-results-and-provides-business-update.html?ref=bullished.co) — globenewswire.com

### More on Rezolute

- [Rezolute Sizes Tumor Hyperinsulinism At $4-5 Billion, With Patients Needing Triple The Vials](https://www.bullished.co/rezolute-sizes-tumor-hyperinsulinism-at-4-5-billion-with-patients-needing-triple-the-vials-c8adbb53/)
- [Jennison Associates Takes A 5.5% Passive Stake In Rezolute, Holding 5.3 Million Shares](https://www.bullished.co/jennison-associates-takes-a-5-5-passive-stake-in-rezolute-holding-5-3-million-shares-2ac28d6a/)
- [Rezolute's CEO Took Home $5,711,410 And Also Chairs The Board, Proxy Shows](https://www.bullished.co/rezolutes-ceo-took-home-5-711-410-and-also-chairs-the-board-proxy-shows-61925309/)

[All Rezolute (RZLT) coverage →](https://www.bullished.co/tag/rzlt/)